Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of KRX-0502 (Ferric Citrate) Dose Regimens in Subjects With Non-Dialysis Dependent Chronic Kidney Disease and Iron-Deficiency Anemia

Next Previous
X
Search
Trial Profile

Study of KRX-0502 (Ferric Citrate) Dose Regimens in Subjects With Non-Dialysis Dependent Chronic Kidney Disease and Iron-Deficiency Anemia

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ferric citrate (Primary)
  • Indications Iron deficiency anaemia
  • Focus Therapeutic Use
  • Acronyms COMPASS
  • Sponsors Akebia Therapeutics; Keryx Biopharmaceuticals

    • Most Recent Events

    • 25 Mar 2021 According to an Akebia Therapeutics media release, data from this trial will be presented at the National Kidney Foundation 2021 Spring Clinical Meetings (NKF SCM21),
    • 09 Oct 2020 According to an Akebia Therapeutics media release, abstract to be presented at ASN Kidney Week are now available online on the ASN Kidney Week abstract portal.
    • 09 Oct 2020 According to an Akebia Therapeutics media release, data from this study will be presented virtually at the American Society of Nephrology Kidney Week 2020 Reimagined (ASN Kidney Week).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top